1834 Investment Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History
Bought
Maintained
Sold
Other funds holding ARKG
1834 Investment Advisors's ARKG Position: Q3 2022 in Review
1834 Investment Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2022, closing a stake of 233 shares — an estimated $7K sold.
1834 Investment Advisors first reported a position in ARKG in Q3 2020 and held it in 8 quarters. The position peaked at $22K in Q2 2021. 311 funds tracked by Wall St. Rank hold ARKG as of Q3 2022.
- 1834 Investment Advisors reported no remaining ARK Genomic Revolution ETF position as of Q3 2022 after selling out during the quarter.
- 1834 Investment Advisors sold 233 ARK Genomic Revolution ETF shares in Q3 2022, an estimated $7K.
- 1834 Investment Advisors first reported a position in ARK Genomic Revolution ETF in Q3 2020 and held it in 8 quarters.
- 1834 Investment Advisors's ARK Genomic Revolution ETF position peaked at $22K in Q2 2021.
- 311 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2022.
Based on 1834 Investment Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.